US FDA wants LABA drugs contraindicated for monotherapy in asthma
19 February 2010
Nancy Faigen
The
US FDA has asked sponsors make significant changes to the data sheets of the long-acting beta-2 adrenergic agonists (LABAs) in order to emphasise that their use is contraindicated in asthma without the concomitant use of an asthma controller such as an inhaled corticosteroid. Single-agent LABAs,...
Please Login to read the full article.
19 February 2010
Nancy Faigen
Please Login to read the full article.
RELATED CONTENT
NEWS
- GSK sees £3 billion wiped off value in response to mixed Phase III Relovair data
- GSK to close three research units, open four more amid hopes for sales growth in 2012
- Nycomed to co-market Orion's Easyhaler products in Europe and MENA region
- Pivotal trials boost Relovair from GSK/ Theravance in COPD
COMMENT
Other Informa Comment
EVENTS
28 February 2012
Pestana Chelsea Bridge Hotel London
04 March 2012
The Marriott World Center, Orlando, Florida
26 March 2012
Copenhagen, Denmark
JOB OF THE WEEK
Promote your vacancy here
